A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy
Takizawa, M.; Hirano, M.; Murakami, N.; Uno, Y.; Kikuchi, T.; Nozawa, H.; Hara, T.; Asaumi, Y.; Kikkawa, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(9): 1647-1650
2002
ISSN/ISBN: 0385-0684 PMID: 12355954 Document Number: 546026
A 54-year-old man suffering from Borrmann type 4 advanced gastric cancer with pancreatic invasion and paraaortic lymph node metastases underwent a total gastrectomy, which was a radical C operation. From postoperative month 4, he visited our hospital with multiple liver metastases and increased lymph node metastases. After chemotherapy with CDDP and 5-FU, CDDP and UFT was administered on an outpatient basis. The effect of this therapy was PD, therefore, docetaxel and 5'-DFUR combination chemotherapy was performed as second line therapy. After 2 courses of this therapy, the size of liver and lymph node metastases was reduced and the effect of this therapy was PR. The patient has undergone 4 courses of this therapy and is maintaining a clinical PR. It is conceivable that docetaxel and 5'-DFUR combination chemotherapy is useful for patients with advanced and recurrent gastric cancer, even if they had been treated with 5-FU administration as first line therapy.